Acrivon Therapeutics announces availability of new press release

Reuters2026/07/21 20:31

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Acrivon posted a press release outlining AACR D3 2026 oral and poster presentations highlighting its AP3 platform, centered on WEE1/PKMYT1 inhibitor ACR-2316.
ACR-2316 Phase 1/2 data cited early tumor shrinkage, including partial responses, across AP3-predicted tumor types not previously sensitive to WEE1-class agents.
Conference presentations scheduled July 22-23 in Boston; ACR-2316 is advancing toward dose expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211630PRIMZONEFULLFEED9765801) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Acrivon Therapeutics announces availability of new press release

You may also like

Crypto prices